It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The diversity of the naïve T cell repertoire drives the replenishment potential and capacity of memory T cells to respond to immune challenges. Attrition of the immune system is associated with an increased prevalence of pathologies in aged individuals, but whether stem cell memory T lymphocytes (TSCM) contribute to such attrition is still unclear. Using single cells RNA sequencing and high-dimensional flow cytometry, we demonstrate that TSCM heterogeneity results from differential engagement of Wnt signaling. In humans, aging is associated with the coupled loss of Wnt/β-catenin signature in CD4 TSCM and systemic increase in the levels of Dickkopf-related protein 1, a natural inhibitor of the Wnt/β-catenin pathway. Functional assays support recent thymic emigrants as the precursors of CD4 TSCM. Our data thus hint that reversing TSCM defects by metabolic targeting of the Wnt/β-catenin pathway may be a viable approach to restore and preserve immune homeostasis in the context of immunological history.
Aging is associated with immune attrition that may impact the effectiveness of the immune system to protect the host from pathogens. Here the authors show that immune aging is associated with alterations in the Wnt/β-catenin signaling and reduced stem cell memory T lymphocytes, hinting the Wnt/β-catenin pathway as a potential therapy target.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Agency for Science Technology and Research (A*STAR), Singapore Immunology Network (SIgN), Biopolis, Republic of Singapore (GRID:grid.185448.4) (ISNI:0000 0004 0637 0221)
2 Agency for Science Technology and Research (A*STAR), Singapore Immunology Network (SIgN), Biopolis, Republic of Singapore (GRID:grid.185448.4) (ISNI:0000 0004 0637 0221); University of Southampton, Clinical and Experimental Sciences, Faculty of Medicine, Southampton, UK (GRID:grid.5491.9) (ISNI:0000 0004 1936 9297)
3 Agency for Science Technology and Research (A*STAR), Singapore Immunology Network (SIgN), Biopolis, Republic of Singapore (GRID:grid.185448.4) (ISNI:0000 0004 0637 0221); National University of Singapore, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, Singapore, Republic of Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431)
4 University of Ulm, Institute of Molecular Medicine, Ulm, Germany (GRID:grid.6582.9) (ISNI:0000 0004 1936 9748)
5 Laboratory of Translational Immunology (LTI), Humanitas Clinical and Research Center, Rozzano, Italy (GRID:grid.6582.9)
6 University of Ulm, Institute of Molecular Medicine, Ulm, Germany (GRID:grid.6582.9) (ISNI:0000 0004 1936 9748); Experimental Hematology and Cancer Biology, CCHMC, Cincinnati, USA (GRID:grid.239573.9) (ISNI:0000 0000 9025 8099)
7 University of Seville, Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital, CSIC, Seville, Spain (GRID:grid.9224.d) (ISNI:0000 0001 2168 1229)
8 University of Sherbrooke, Department of Medicine, Faculty of Medicine, Sherbrooke, Canada (GRID:grid.86715.3d) (ISNI:0000 0000 9064 6198)
9 University of Malaya, Centre of Excellence for Research in AIDS (CERiA), Kuala Lumpur, Malaysia (GRID:grid.10347.31) (ISNI:0000 0001 2308 5949); University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); University of Malaya, Faculty of Medicine, Kuala Lumpur, Malaysia (GRID:grid.10347.31) (ISNI:0000 0001 2308 5949)
10 University of Malaya, Centre of Excellence for Research in AIDS (CERiA), Kuala Lumpur, Malaysia (GRID:grid.10347.31) (ISNI:0000 0001 2308 5949); University of Malaya, Faculty of Medicine, Kuala Lumpur, Malaysia (GRID:grid.10347.31) (ISNI:0000 0001 2308 5949)
11 National University of Singapore, Gerontology Research Programme and Department of Psychological Medicine, Yong Loo Lin School of Medicine, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431)
12 Laboratory of Translational Immunology (LTI), Humanitas Clinical and Research Center, Rozzano, Italy (GRID:grid.4280.e)
13 Agency for Science Technology and Research (A*STAR), Singapore Immunology Network (SIgN), Biopolis, Republic of Singapore (GRID:grid.185448.4) (ISNI:0000 0004 0637 0221); National University of Singapore, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, Singapore, Republic of Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431); University of Sherbrooke, Department of Medicine, Faculty of Medicine, Sherbrooke, Canada (GRID:grid.86715.3d) (ISNI:0000 0000 9064 6198)